ACELYRIN Inc (SLRN) 뉴스

Form 425 - Prospectuses and communications, business combinations

Form 425 - Prospectuses and communications, business combinations

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS...

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04...

Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm

Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm PR Newswire NEW YORK, Feb. 21...

Form 425 - Prospectuses and communications, business combinations

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma...

Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm

Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm PR Newswire NEW YORK, Feb. 10...

Form 425 - Prospectuses and communications, business combinations

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC. PR Newswire NEW YORK, Feb. 7, 2025 NEW YORK, Feb. 7, 2025...

Form 8-K - Current report

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for...

Form 8-K - Current report